Hybridoma generation for therapeutic antibody drug discovery and applications
Therapeutic antibody drugs have recently experienced explosive growth. Within oncology research alone, 14 therapeutic antibody drugs received FDA approval for new treatments or indications during 2015. Additionally, more than 300 therapeutic antibody drugs are in ongoing clinical trials. Driven by the increase in biomarker discovery, more and more therapeutic antibody drugs are set to enter the market with increased competition. Therefore, to maximize the success of therapeutic antibody drug development, it is essential to thoroughly vet antibody drug candidates at every step of the process. This webinar will review the current platforms for generating antibodies and discuss the screening and characterization technologies required for rational selection of lead therapeutic antibody drug candidates. We will examine key case studies demonstrating appropriate use of cutting edge high throughput screening platforms to guide hybridoma clone selection. Ultimately, attendees will understand how these approaches integrate with both upstream and downstream therapeutic antibody drug discovery methodologies.
|Custom Antibody Solutions: Supporting every step along the path of therapeutic antibody development.|
|Hybridoma Generation for Therapeutic Antibody Discovery Service||DNA Immunization Service||Anti-idiotypic Antibody Service|